REGN5458, a Bispecific BCMAxCD3 T Cell Engaging Antibody, Demonstrates Robust In Vitro and In Vivo Anti-Tumor Efficacy in Multiple Myeloma Models, Comparable to That of BCMA CAR T Cells

导出原文传递

翻译打印收藏纠错

作者： Dilillo, David J. ^[1] ; Olson, Kara ^[2] ; Mohrs, Katja ; Meagher, T. Craig ; Bray, Kevin ; Sineshchekova, Olga ; Startz, Thomas ; Retter, Marc ; Godin, Stephen ; Delfino, Frank ; Lin, John ; Smith, Eric ; Thurston, Olin Gavin ; Kirshner, Jessica R.

作者单位： Regeneron Pharmaceut, Tarrytown, NY USA ^[1] Regeneron Pharmaceut, New York, NY USA ^[2]

发布时间 2020-08-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

Blood

2018年Novel Treatment Appr期

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

REGN5458, a Bispecific BCMAxCD3 T Cell Engaging Antibody, Demonstrates Robust In Vitro and In Vivo Anti-Tumor Efficacy in Multiple Myeloma Models, Comparable to That of BCMA CAR T Cells

Blood

相似文献

Blood

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

REGN5458, a Bispecific BCMAxCD3 T Cell Engaging Antibody, Demonstrates Robust In Vitro and In Vivo Anti-Tumor Efficacy in Multiple Myeloma Models, Comparable to That of BCMA CAR T Cells

Blood

相似文献

Blood

相关期刊

检索历史清除